Latest & greatest articles for breast cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on breast cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on breast cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for breast cancer

1. Common osteoporosis drugs may prevent breast cancer spreading to bone

Common osteoporosis drugs may prevent breast cancer spreading to bone Signal - Common osteoporosis drugs may prevent breast cancer spreading to bone Dissemination Centre Discover Portal NIHR DC Discover Common osteoporosis drugs may prevent breast cancer spreading to bone Published on 13 March 2018 Drugs commonly prescribed to prevent bone thinning probably help prevent the spread of early breast cancer to the bones in a few women, when taken in addition to standard cancer therapies. However (...) , the overall benefits may be small, for example preventing spread to bone or death in about one extra woman in every 100 treated for about five years. This is a complex area because many of the treatments for breast cancer are known to worsen bone thinning, but there are other bone strengthening benefits to these drugs. This large review of 44 studies with more than 37,000 participants looked at women with either early breast cancer or advanced breast cancer with or without bone involvement. The reviewers

NIHR Dissemination Centre2019

2. Delaying chemotherapy after breast cancer surgery may reduce survival chances

Delaying chemotherapy after breast cancer surgery may reduce survival chances Signal - Delaying chemotherapy after breast cancer surgery may reduce survival chances Dissemination Centre Discover Portal NIHR DC Discover Delaying chemotherapy after breast cancer surgery may reduce survival chances Published on 31 January 2017 Delaying chemotherapy after breast cancer surgery may slightly decrease a woman’s chances of survival. A review found about a 5% increase in the relative risk of death. Many (...) women are offered chemotherapy soon after breast cancer surgery, called adjuvant chemotherapy. Chemotherapy is usually started after the surgical wounds have healed but the effect of any delay to this was unclear. These researchers calculated the risk from outcomes for almost 30,000 women treated with adjuvant chemotherapy, from studies in Europe and North America. The absolute risk of death for any woman will depend on her individual cancer stage and characteristics. A four week delay could add

NIHR Dissemination Centre2019

3. Pertuzumab (Perjeta) - in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer

Pertuzumab (Perjeta) - in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer 1 Published 14 January 2019 1 a SMC2120 pertuzumab 420mg concentrate for solution for infusion (Perjeta®) Roche Products Limited 7 December 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised as follows: ADVICE (...) : following a third resubmission assessed under the orphan equivalent process pertuzumab (Perjeta ® ) is accepted for use within NHSScotland. Indication under review: In combination with trastuzumab and docetaxel, in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease. Addition of pertuzumab to current first-line treatment, trastuzumab plus docetaxel, significantly

Scottish Medicines Consortium2019

4. Trastuzumab (Ogivri) - breast cancer or stomach cancer

Trastuzumab (Ogivri) - breast cancer or stomach cancer 1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions 1. NAME OF THE MEDICINAL PRODUCT Ogivri 150 mg powder for concentrate for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One (...) for solution for infusion (powder for concentrate). White to pale yellow lyophilised powder. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Breast cancer Metastatic breast cancer Ogivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC): - as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless

European Medicines Agency - EPARs2019

5. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer

Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer T T umour profiling tests to guide adjuvant umour profiling tests to guide adjuvant chemother chemotherap apy decisions in early breast y decisions in early breast cancer cancer Diagnostics guidance Published: 19 December 2018 nice.org.uk/guidance/dg34 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Y Y our responsibility our (...) of implementing NICE recommendations wherever possible. Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (DG34) © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 56Contents Contents 1 Recommendations 4 2 Clinical need and practice 6 The problem addressed 6 The condition 7 The diagnostics and care pathways 7 3 The diagnostic tests 9 The interventions 9 The comparator 13 4 Evidence 14

National Institute for Health and Clinical Excellence - Diagnostics Guidance2019

6. Adjuvant Endocrine Therapy for Women With Hormone Receptor?Positive Breast Cancer

Adjuvant Endocrine Therapy for Women With Hormone Receptor?Positive Breast Cancer ');//--> ');//--> Search in: Menu Captcha ASCO Family of Sites Journals Publications Education Other Sites 2318 Mill Road, Suite 800, Alexandria, VA 22314 © 2018 American Society of Clinical Oncology |

American Society of Clinical Oncology Guidelines2019

7. A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer

A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer 29730319 2018 11 24 1532-821X 99 12 2018 Dec Archives of physical medicine and rehabilitation Arch Phys Med Rehabil A Systematic Review and Meta-Analysis of the Safety, Feasibility, and Effect of Exercise in Women With Stage II+ Breast Cancer. 2621-2636 S0003-9993(18)30280-6 10.1016/j.apmr.2018.03.026 To systematically evaluate the safety, feasibility, and effect (...) of exercise among women with stage II+ breast cancer. CINAHL, Cochrane, Ebscohost, MEDLINE, Pubmed, ProQuest Health and Medical Complete, ProQuest Nursing and Allied Health Source, Science Direct and SPORTDiscus were searched for articles published before March 1, 2017. Randomized, controlled, exercise trials involving at least 50% of women diagnosed with stage II+ breast cancer were included. Risk of bias was assessed and adverse event severity was classified using the Common Terminology Criteria

EvidenceUpdates2019

8. Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies.

Breast Cancer Risk After Recent Childbirth: A Pooled Analysis of 15 Prospective Studies. Background: Parity is widely recognized as protective for breast cancer, but breast cancer risk may be increased shortly after childbirth. Whether this risk varies with breastfeeding, family history of breast cancer, or specific tumor subtype has rarely been evaluated. Objective: To characterize breast cancer risk in relation to recent childbirth. Design: Pooled analysis of individual-level data from 15 (...) prospective cohort studies. Setting: The international Premenopausal Breast Cancer Collaborative Group. Participants: Women younger than 55 years. Measurements: During 9.6 million person-years of follow-up, 18 826 incident cases of breast cancer were diagnosed. Hazard ratios (HRs) and 95% CIs for breast cancer were calculated using Cox proportional hazards regression. Results: Compared with nulliparous women, parous women had an HR for breast cancer that peaked about 5 years after birth (HR, 1.80 [95% CI

Annals of Internal Medicine2018

9. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. BACKGROUND: Patients who have residual invasive breast cancer after receiving neoadjuvant chemotherapy plus human epidermal growth factor receptor 2 (HER2)-targeted therapy have a worse prognosis than those who have no residual cancer. Trastuzumab emtansine (T-DM1), an antibody-drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, provides benefit (...) in patients with metastatic breast cancer that was previously treated with chemotherapy plus HER2-targeted therapy. METHODS: We conducted a phase 3, open-label trial involving patients with HER2-positive early breast cancer who were found to have residual invasive disease in the breast or axilla at surgery after receiving neoadjuvant therapy containing a taxane (with or without anthracycline) and trastuzumab. Patients were randomly assigned to receive adjuvant T-DM1 or trastuzumab for 14 cycles

NEJM2018

10. Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis

Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis 30312200 2018 10 12 1528-1140 2018 Oct 11 Annals of surgery Ann. Surg. Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer: A Systematic Review and Meta-analysis. 10.1097/SLA.0000000000003075 The aim of this study was to perform (...) a systematic review and meta-analysis to assess the accuracy of different surgical axillary staging procedures compared with ALND. Optimal axillary staging after neoadjuvant systemic therapy (NST) in node-positive breast cancer is an area of controversy. Several less invasive procedures, such as sentinel lymph node biopsy (SLNB), marking axillary lymph node with radioactive iodine seed (MARI), and targeted axillary dissection (a combination of SLNB and a MARI-like procedure), have been proposed to replace

EvidenceUpdates2018

11. Limited Evidence Suggests Periodontal Disease Is Associated with a Slightly Increased Risk of Breast Cancer

Limited Evidence Suggests Periodontal Disease Is Associated with a Slightly Increased Risk of Breast Cancer UTCAT3364, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Limited Evidence Suggests Periodontal Disease Is Associated with a Slightly Increased Risk of Breast Cancer Clinical Question In female patients with periodontal disease, is there an increased risk for breast cancer when compared to women without (...) periodontal disease? Clinical Bottom Line Patients with periodontitis have a slightly increased risk of breast cancer according to limited evidence from one meta-analysis and a prospective cohort study. History of smoking may play a role in this relationship and more evidence is required before specific recommendations can be made to patients with periodontitis. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1

UTHSCSA Dental School CAT Library2018

12. Pertuzumab (Perjeta) - treatment of adult patients with HER2 positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence

Pertuzumab (Perjeta) - treatment of adult patients with HER2 positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence 1 Published 10 December 2018 1 SMC2119 pertuzumab 420mg concentrate for solution for infusion (Perjeta®) Roche Products Limited Resubmission 9 November 2018 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use (...) in NHSScotland. The advice is summarised as follows: ADVICE: following a second resubmission assessed under the orphan medicine process pertuzumab (Perjeta ® ) is accepted for use within NHSScotland. Indication under review: for use in combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. In a phase II study conducted in women with locally advanced, inflammatory

Scottish Medicines Consortium2018

13. Risk factors for breast cancer: A review of the evidence 2018

Risk factors for breast cancer: A review of the evidence 2018 Risk factors for breast cancer: A review of the evidence 2018 Breast cancer risk factors: A review of the evidence i Risk factors for breast cancer: A review of the evidence was prepared and produced by: Cancer Australia Locked Bag 3 Strawberry Hills NSW 2012 Australia Tel: +61 2 9357 9400 Fax: +61 2 9357 9477 canceraustralia.gov.au © Cancer Australia 2018. ISBN Print: 978–1–74127–336–6 ISBN Online: 978–1–74127–337–3 Recommended (...) citation Cancer Australia, 2018. Risk factors for breast cancer: A review of the evidence, Cancer Australia, Surry Hills, NSW. Risk factors for breast cancer: A review of the evidence can be downloaded from the Cancer Australia website: canceraustralia.gov.au Copyright statements Internet sites This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within

Cancer Australia2018

14. Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer

Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer 30311642 2018 10 12 1365-2168 105 12 2018 Nov The British journal of surgery Br J Surg Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. 1541-1552 10.1002/bjs.10986 Neoadjuvant chemotherapy for breast cancer has the potential to achieve a pathological complete (...) response in up to 40 per cent of patients, converting disease that was initially node-positive to node-negative. This has raised the question of whether sentinel lymph node biopsy could be an alternative to axillary lymph node dissection in these patients. The aim was to undertake a systematic review and meta-analysis of the accuracy and reliability of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer. A literature search

EvidenceUpdates2018

15. Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk

Recommendations on screening for breast cancer in women 40-74 years of age who are not at increased risk Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer | CMAJ Main menu User menu Search Search for this keyword Search for this keyword Guideline Recommendations on screening for breast cancer in women aged 40–74 years who are not at increased risk for breast cancer Scott Klarenbach , Nicki Sims-Jones , Gabriela Lewin (...) POINTS Low-certainty evidence indicates that screening for breast cancer with mammography results in a modest reduction in breast cancer mortality for women aged 40 to 74 years; the absolute benefit is lowest for women younger than 50 years. Screening may lead to overdiagnosis, resulting in unnecessary treatment of cancer that would not have caused harm in a woman’s lifetime and false-positive results that can lead to both physical and psychological consequences; overdiagnosis and false-positives

Canadian Task Force on Preventive Health Care2018

16. Breast Cancer Risk Factors At a Glance

Breast Cancer Risk Factors At a Glance Age 50 years old 30 years old Height 172 cm 162 cm ( average female height in Australia ) Reproductive factors Family history and genetic factors Lifestyle factors Personal factors VS. VS. 152 cm 162 cm ( average female height in Australia ) Mammographic breast density VS. Extremely dense breasts averagely dense breasts VS. Body mass index ( postmenopausal women ) VS. Adult weight gain ( postmenopausal women ) Weight gain (5kg) no weight gain VS. Weight (...) gain (10kg) Weight gain (20kg) Alcohol consumption 2 drinks per day no daily alcohol consumption VS. Physical activity Most active least active ( postmenopausal women ) VS. 4 drinks per day 6 drinks per day Breast Cancer Risk Factors At a Glance Decreased risk Increased risk 1 2 3 4 5 6 7 8 910 0.5 0.33 0.25 0.2 0.125 0.1 10 1.17 0.85 2.14 1.12 1.25 1.40 1.06 1.12 1.26 1.15 1.31 1.50 0.87 VS. VS. no weight gain VS. no weight gain VS. no daily alcohol consumption VS. no daily alcohol consumption VS

Cancer Australia2018

17. HER2 Testing in Breast Cancer - 2018 Focused Update

HER2 Testing in Breast Cancer - 2018 Focused Update HER2 Testing in Breast Cancer -… | College of American Pathologists Cap icon Group CAP_logo_rgb[1] User Toggle Navigation Menu Search Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow Down Arrow HER2 Testing in Breast Cancer - 2018 Focused Update HER2 Testing in Breast Cancer - 2018 Focused Update To address new information made available since the 2013 “Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer (...) 2+ (equivocal) to the original FDA-approved criteria. Repeat HER2 testing on a surgical specimen if the initially tested core biopsy is negative is no longer stated as mandatory. A new HER2 test may (no longer should ) be ordered on the excision specimen on the basis of some criteria (such as tumor grade 3). A more rigorous interpretation criteria of the less common patterns that can be seen in about 5% of all cases when HER2 status in breast cancer is evaluated using a dual-probe ISH testing

College of American Pathologists2018

18. 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer 30456299 2018 12 07 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer 21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. 37 10.1038/s41523-018-0090-6 The NSABP B-20 prospective-retrospective study of the 21-gene Oncotype DX Breast Cancer Recurrence Score® test predicted benefit from addition of chemotherapy to tamoxifen in node-negative, estrogen-receptor positive breast cancer (...) eng U10 CA180822 CA NCI NIH HHS United States U10 CA180868 CA NCI NIH HHS United States U24 CA196067 CA NCI NIH HHS United States Journal Article 2018 11 14 United States NPJ Breast Cancer 101674891 2374-4677 Dr. Mamounas: Genomic Health, Inc.: Consultant, Honoraria (Speaker); Biotheranostics: Consultant. Dr. Paik discloses being listed as one of the inventors of OncotypeDx in the patents, but all rights have been transferred to NSABP Foundation, resulting in no financial interest. Dr. Shak

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro

19. Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.

Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis. BACKGROUND: Originator trastuzumab (Herceptin®; H) is an antibody-targeted therapy to treat patients with human epidermal growth factor receptor 2-positive (HER2+) early breast cancer (EBC). We investigated the overall survival (OS) advantage conferred by the addition of H to chemotherapy for HER2+ EBC patients and how the OS advantage changed over time. METHODS: A systematic

Systematic Reviews2018 Full Text: Link to full Text with Trip Pro

20. mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential

mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential 30456298 2018 12 07 2374-4677 4 2018 NPJ breast cancer NPJ Breast Cancer mTORC1 is a key mediator of RON-dependent breast cancer metastasis with therapeutic potential. 36 10.1038/s41523-018-0091-5 Metastasis is the biggest challenge in treating breast cancer, and it kills >40,000 breast cancer patients annually in the US. Aberrant expression of the RON receptor tyrosine kinase in breast tumors (...) correlates with poor prognosis and has been shown to promote metastasis. However, the molecular mechanisms that govern how RON promotes metastasis, and how to block it, are still largely unknown. We sought to determine critical effectors of RON using a combination of mutational and pharmacologic strategies. High-throughput proteomic analysis of breast cancer cells upon activation of RON showed robust phosphorylation of ribosomal protein S6. Further analysis revealed that RON strongly signals through

NPJ breast cancer2018 Full Text: Link to full Text with Trip Pro